Clarus Therapeutics Inc

Type: Company
Name: Clarus Therapeutics Inc
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

Patent Issued for Pharmaceutical Delivery Systems for Hydrophobic Drugs and Compositions Comprising Same

By a News Reporter-Staff News Editor at Biotech Week According to news reporting originating from Alexandria, Virginia, by NewsRx journalists, a patent by the inventors Dudley, Robert E. (Rosemary Beach, FL); Constantinides, Panayiotis P. (Gurnee, IL), ... [Published Pharmacy Choice - Jul 30 2014]
First reported Jul 29 2014 - Updated Jul 30 2014 - 1 reports

FDA Seeks Answers From Advisory Panels As Testosterone Lawsuits Mount Against "Low T" Drug Makers

) Chicago, IL -- Wright & Shulte LLC has learned that the U.S. Food & Drug Administration (FDA) has called for a meeting on September 17 for two of its advisory panels to weigh in on the potential for testosterone replacement therapy drugs to cause heart ... [Published EMAILWIRE.com - Jul 29 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

Upcoming AdComms By Subject Matter

In February and in April I posted a listing of upcoming advisory committees by subject matter and people seemed to like this way of looking at it, so I try to repeat it every so often.  Today is every so often.  It is just a different way of ... [Published Eye on FDA - Jul 28 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

Sarepta science officer Krieg 'terminated' quietly

Sarepta TherapeuticsArthur Krieg was let go from his senior VP and CSO position.Biotech> GliaCure has appointed Joseph Zakrzewski to its board of directors. Release> Cannabis Science has appointed Roscoe Moore for a second term on its scientific ... [Published FierceBiotech - Jul 25 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

Do testosterone meds boost heart attack risks? FDA asks advisory panels to weigh the data

The FDA has zoomed in on testosterone products for the cardiovascular risks they might pose to consumers, even slapping a new warning on their official labels. Now, the agency has called a special advisory committee meeting to probe two trials that flagged ... [Published FiercePharma - Jul 22 2014]
First reported Jul 21 2014 - Updated Jul 21 2014 - 1 reports

Health and Human Services Department (HHS); Food and Drug Administration (FDA) (F.R. Page 42338) - Meeting

Federal Information & News Dispatch, Inc.**NewTIME: 8 a.m.EVENT: Health and Human Services Department (HHS); Food and Drug Administration (FDA) (F.R. Page 42338) holds a joint meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee and ... [Published Insurance News Net - Jul 21 2014]
First reported Jul 21 2014 - Updated Jul 21 2014 - 1 reports

Clarus Therapeutics Expands Board of Directors With Appointment of Two Pharmaceutical Industry Veterans

(GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc., a men's health specialty pharmaceutical company focused on the development and commercialization of REXTORO ® , an oral testosterone (T) replacement product, today announced the expansion of its Board of ... [Published TVNewsCheck - Jul 21 2014]
First reported Jun 22 2014 - Updated Jun 23 2014 - 4 reports

Clarus Therapeutics Presents Phase 3 Data For REXTORO® For Men With Hypogonadism

6/23/2014 7:45:16 AMNORTHBROOK, Ill., June 22, 2014 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc., a men's health specialty pharmaceutical company focused on the development and commercialization of REXTORO ( (Testosterone Undecanoate), an oral testosterone ... [Published BioSpace - Jun 23 2014]
First reported May 27 2014 - Updated May 27 2014 - 1 reports

The Daily Startup: VCs Feeling Confident About Gene Therapy Again

Gene therapy investments soared in the middle of the last decade before falling off a cliff. Now the sector is rebounding. Global venture investment in gene therapies peaked in 2006 with $507.7 million, according to data from Dow Jones VentureSource, ... [Published WSJ.com: Venture Capital Dispatch - May 27 2014]
First reported May 21 2014 - Updated May 21 2014 - 1 reports

Clarus Therapeutics Appoints Patrick Shea Chief Commercial Officer

(GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc., a men's health specialty pharmaceutical company focused on the development and commercialization of REXTORO, an oral testosterone (T) replacement product, today announced that Patrick Shea has joined the ... [Published GlobeNewswire - May 21 2014]

Quotes

In addition to obtaining background information on this patent, NewsRx editors also obtained the inventors' summary information for this patent: "In one embodiment of the present invention, a pharmaceutical composition is provided comprising testosterone palmitate (TP), or a testosterone ester thereof, and two or more lipid components at least the first of which comprises a hydrophilic surfactant and at least the second of which comprises a lipophilic surfactant that provides for the controlled release of TP, said lipid components together providing for the solubilization of TP. The pharmaceutical composition may further comprise at least three lipid components at least the first of which comprises a hydrophilic surfactant, at least the second of which comprises a lipophilic surfactant that provides for the controlled release of TP and at least the third of which comprises a lipophilic surfactant that further provides for the solubilization of TP. As well, the pharmaceutical composition may further comprise a second lipid-soluble therapeutic agent, such as a synthetic progestin. Formulations comprising same may be preferably in the form of an orally active male contraceptive."
"Clarus is fortunate to strengthen its Board of Directors with the additions of these two seasoned pharmaceutical industry executives. Elizabeth is a proven commercialization leader with more than 30 years of experience in pharmaceuticals, healthcare management services and consumer healthcare products. During her career, she led the growth and transformation of a number of brands and businesses ranging from specialty to large scale pharmaceutical portfolios" said Dr. Robert E Dudley, Clarus President, CEO and Chairman of the Board of Directors
...met the efficacy endpoint in both studies with the convenience of oral administration," said Robert E Dudley, Ph D , CEO of Clarus Therapeutics. "The data underscore REXTORO's potential as a well-tolerated, oral therapeutic that eliminates the medication transference risks related to contact with gel-based T-replacement therapies."

More Content

All (18) | News (11) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (0) | Press Releases (5)
sort by: Date | Relevance
Patent Issued for Pharmaceutical Delivery Syste... [Published Pharmacy Choice - Jul 30 2014]
FDA Seeks Answers From Advisory Panels As Testo... [Published EMAILWIRE.com - Jul 29 2014]
Upcoming AdComms By Subject Matter [Published Eye on FDA - Jul 28 2014]
Sarepta science officer Krieg 'terminated' quietly [Published FierceBiotech - Jul 25 2014]
Do testosterone meds boost heart attack risks? ... [Published FiercePharma - Jul 22 2014]
Health and Human Services Department (HHS); Foo... [Published Insurance News Net - Jul 21 2014]
Clarus Therapeutics Expands Board of Directors ... [Published GlobeNewswire: Acquisitions News - Jul 21 2014]
Clarus Therapeutics Expands Board of Directors ... [Published TVNewsCheck - Jul 21 2014]
Clarus Therapeutics Presents Phase 3 Data For R... [Published BioSpace - Jun 23 2014]
Clarus Therapeutics Inc presents phase 3 data f... [Published Reuters - Jun 23 2014]
Clarus Therapeutics Presents Phase 3 Data for R... [Published GlobeNewswire: Acquisitions News - Jun 22 2014]
Clarus Therapeutics Presents Phase 3 Data for R... [Published Wall Street Select - Jun 22 2014]
Clarus Therapeutics Presents Phase 3 Data for R... [Published Town Hall - Jun 22 2014]
Clarus Therapeutics Secures $31.5 Million in Fi... [Published GlobeNewswire: Advertising News - Jun 12 2014]
Clarus Therapeutics to Present Phase 3 Data for... [Published GlobeNewswire: Advertising News - May 28 2014]
The Daily Startup: VCs Feeling Confident About ... [Published WSJ.com: Venture Capital Dispatch - May 27 2014]
Clarus Therapeutics Appoints Patrick Shea Chief... [Published GlobeNewswire - May 21 2014]
Clarus Therapeutics Appoints John Gargiulo Chie... [Published GlobeNewswire: Acquisitions News - Mar 17 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Upcoming AdComms By Subject Matter [Published Eye on FDA - Jul 28 2014]
In February and in April I posted a listing of upcoming advisory committees by subject matter and people seemed to like this way of looking at it, so I try to repeat it every so often.  Today is every so often.  It is just a different way of ...
The Daily Startup: VCs Feeling Confident About ... [Published WSJ.com: Venture Capital Dispatch - May 27 2014]
Gene therapy investments soared in the middle of the last decade before falling off a cliff. Now the sector is rebounding. Global venture investment in gene therapies peaked in 2006 with $507.7 million, according to data from Dow Jones VentureSource, ...
1

Press Releases

sort by: Date | Relevance
Clarus Therapeutics Expands Board of Directors ... [Published GlobeNewswire: Acquisitions News - Jul 21 2014]
Clarus Therapeutics Presents Phase 3 Data for R... [Published GlobeNewswire: Acquisitions News - Jun 22 2014]
Clarus Therapeutics Secures $31.5 Million in Fi... [Published GlobeNewswire: Advertising News - Jun 12 2014]
Clarus Therapeutics to Present Phase 3 Data for... [Published GlobeNewswire: Advertising News - May 28 2014]
Clarus Therapeutics Appoints John Gargiulo Chie... [Published GlobeNewswire: Acquisitions News - Mar 17 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.